Results 31 to 40 of about 182,500 (270)
Pembrolizumab, an anti‐programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established.
Katsuhiro Ito +15 more
doaj +1 more source
Chemo-immunotherapy consisting of pemetrexed and pembrolizumab is first line therapy for individuals with non-squamous non-small cell lung cancer without ALK or EGFR mutations.
Michael H. Storandt, Rishi Seth
doaj +1 more source
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma [PDF]
Purpose: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study.
Chesney, Jason A; https://orcid.org/ +42 more
core +1 more source
Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50%.
Zuan Lin
doaj +1 more source
Unilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab [PDF]
A man in his 80s with metastatic melanoma presented with progressive dyspnea on exertion and dry cough after 7 cycles of pembrolizumab monotherapy. He was initially treated with antibiotics for community acquired pneumonia; however, his symptoms recurred
Christine Minerowicz +3 more
core
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival ...
Philippe Merle +19 more
doaj +1 more source
Pembrolizumab-induced follicular eruption and response to isotretinoin [PDF]
Background: Pembrolizumab is a monoclonal antibody targeting PD-1. Folliculitis secondary to pembrolizumab has rarely been reported in the treatment of malignant melanoma.
Power, Derek G. +3 more
core +1 more source
Background Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer.
Teppei Sugano +13 more
doaj +1 more source
Pembrolizumab: review of its current therapeutic uses [PDF]
Background: Pembrolizumab is a humanized monoclonal antibody approved for human use in 2014 by the Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency (EMA).
Silva, Rui +2 more
core +1 more source
A 66-year-old Japanese man with recurrent adenocarcinoma of the lung p-stage IIIA (pT2bN2M0; version 8) on pembrolizumab was present with gradually worsening dyspnea.
Ryo Ueno +4 more
doaj +1 more source

